NCT01048268

Glucose-dependent Insulinotropic Polypeptide - New Role as Blood Glucose Stabilizer?

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: University Hospital, Gentofte, Copenhagen · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine whether glucose-dependent insulinotropic polypeptide (GIP) has a stabilizing function on the blood glucose

Detailed description

The aim of the study is to investigate the effect of GIP on the glucagon secretion during hyper-, eu- and hypoglycemia in healthy volunteers, patients with type 1 diabetes mellitus and patients with type 2 diabetes mellitus. From this, we will evaluate GIP's role as blood sugar stabilizer.

Conditions

• Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	glucose-dependent insulinotropic polypeptide	For the first 20 min of the experiment the volunteers will receive GIP at 4 pmol/kg body weight. For the following 40 minutes the volunteers will receive 2 pmol/kg body weight
DRUG	Placebo	copy GIP infusion rates

Timeline

• Start date: 2009-12-01
• Primary completion: 2014-04-01
• Completion: 2014-04-01
• First posted: 2010-01-13
• Last updated: 2015-07-14

Locations

1 site across 1 country: Denmark